{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:12Z","timestamp":1786120272567,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1097\/cco.0b013e328352ead2","type":"journal-article","created":{"date-parts":[[2012,4,3]],"date-time":"2012-04-03T10:12:07Z","timestamp":1333447927000},"page":"376-380","source":"Crossref","is-referenced-by-count":21,"title":["Predictive factors for poor prognosis febrile neutropenia"],"prefix":"10.1097","volume":"24","author":[{"given":"Shin","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Seon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"R2-6-20210128","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients.","volume":"18","author":"Klastersky","year":"2000","journal-title":"J Clin Oncol"},{"key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.seminoncol.2011.03.013","article-title":"Management of the cancer patient with infection and neutropenia.","volume":"38","author":"Rapoport","year":"2011","journal-title":"Semin Oncol"},{"key":"R4-6-20210128","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1002\/cncr.25332","article-title":"Risk of mortality in patients with cancer who experience febrile neutropenia.","volume":"116","author":"Lyman","year":"2010","journal-title":"Cancer"},{"key":"R5-6-20210128","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/cncr.20983","article-title":"Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.","volume":"103","author":"Caggiano","year":"2005","journal-title":"Cancer"},{"key":"R6-6-20210128","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/bjc.2011.284","article-title":"Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients.","volume":"105","author":"Carmona-Bayonas","year":"2011","journal-title":"Br J Cancer"},{"key":"R7-6-20210128","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1200\/JCO.2005.03.9909","article-title":"Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.","volume":"24","author":"Klastersky","year":"2006","journal-title":"J Clin Oncol"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00520-010-0928-4","article-title":"Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.","volume":"19","author":"Ahn","year":"2011","journal-title":"Support Care Cancer"},{"key":"R10-6-20210128","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00520-010-1017-4","article-title":"Clinical factors predicting bacteremia in low-risk febrile neutropenia after anticancer chemotherapy.","volume":"19","author":"Ha","year":"2011","journal-title":"Support Care Cancer"},{"key":"R11-6-20210128","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00134-002-1560-7","article-title":"Neutropenia and the development of the systemic inflammatory response syndrome.","volume":"29","author":"Regazzoni","year":"2003","journal-title":"Intensive Care Med"},{"key":"R12-6-20210128","doi-asserted-by":"crossref","first-page":"979","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00008","article-title":"Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.","volume":"142","author":"Gafter-Gvili","year":"2005","journal-title":"Ann Intern Med"},{"key":"R13-6-20210128","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"R14-6-20210128","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.ijantimicag.2007.06.012","article-title":"Bacteraemia in febrile neutropenic cancer patients.","volume":"30","author":"Klastersky","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"R15-6-20210128","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.1992.10.2.316","article-title":"Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule.","volume":"10","author":"Talcott","year":"1992","journal-title":"J Clin Oncol"},{"key":"R16-6-20210128","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2354.2007.00780.x","article-title":"Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10.","volume":"16","author":"Uys","year":"2007","journal-title":"Eur J Cancer Care (Engl)"},{"key":"R17-6-20210128","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00520-010-0993-8","article-title":"Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network.","volume":"19","author":"Hui","year":"2011","journal-title":"Support Care Cancer"},{"key":"R18-6-20210128","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00520-007-0334-8","article-title":"Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.","volume":"16","author":"Innes","year":"2008","journal-title":"Support Care Cancer"},{"key":"R19-6-20210128","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00520-004-0614-5","article-title":"Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.","volume":"12","author":"Uys","year":"2004","journal-title":"Support Care Cancer"},{"key":"R20-6-20210128","first-page":"1001","article-title":"Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter Support Care C","volume":"19","author":"Paesmans","year":"2011","journal-title":"ancer"},{"key":"R21-6-20210128","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1001\/archinte.1988.00380120031007","article-title":"The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation.","volume":"148","author":"Talcott","year":"1988","journal-title":"Arch Intern Med"},{"key":"R22-6-20210128","first-page":"643","article-title":"Diagnostic value of procalcitonin serum levels in comparison with C-reactive protein in allogeneic stem cell transplantation.","volume":"87","author":"Hambach","year":"2002","journal-title":"Haematologica"},{"key":"R23-6-20210128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/003655499750006254","article-title":"Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8.","volume":"31","author":"Engel","year":"1999","journal-title":"Scand J Infect Dis"},{"key":"R24-6-20210128","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1469-0691.2004.00883.x","article-title":"Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study.","volume":"10","author":"Giamarellou","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"R25-6-20210128","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/00365540410020217","article-title":"Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia.","volume":"36","author":"Persson","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"R26-6-20210128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.shk.0000215319.06866.bd","article-title":"Prognostic value of interleukin 6, procalcitonin, and C-reactive protein levels in intensive care unit patients during first increase of fever.","volume":"26","author":"Fraunberger","year":"2006","journal-title":"Shock"},{"key":"R27-6-20210128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10156-011-0283-5","article-title":"Identifying risk factors for refractory febrile neutropenia in patients with lung cancer.","volume":"18","author":"Fujita","year":"2012","journal-title":"J Infect Chemother"},{"key":"R28-6-20210128","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s15010-008-7374-y","article-title":"The role of procalcitonin in febrile neutropenic patients: review of the literature.","volume":"36","author":"Sakr","year":"2008","journal-title":"Infection"},{"key":"R29-6-20210128","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.leukres.2011.06.014","article-title":"Procalcitonin is a useful marker of infection in neutropenia.","volume":"35","author":"Koivula","year":"2011","journal-title":"Leuk Res"},{"key":"R30-6-20210128","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3109\/00365548.2011.554855","article-title":"Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia.","volume":"43","author":"Koivula","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"R31-6-20210128","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00520-006-0081-2","article-title":"Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignancies.","volume":"14","author":"von Lilienfeld-Toal M, Schneider","year":"2006","journal-title":"Support Care Cancer"},{"key":"R32-6-20210128","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00011-009-0100-0","article-title":"Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia.","volume":"59","author":"Hatzistilianou","year":"2010","journal-title":"Inflamm Res"},{"key":"R33-6-20210128","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coi.2009.01.009","article-title":"TREM and TREM-like receptors in inflammation and disease.","volume":"21","author":"Ford","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"R34-6-20210128","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00134-008-1333-z","article-title":"Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in bacterial infection: a meta-analysis.","volume":"35","author":"Jiyong","year":"2009","journal-title":"Intensive Care Med"},{"key":"R36-6-20210128","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/CCM.0b013e31820a92dc","article-title":"Soluble triggering receptor expressed on myeloid cells-1 as an infection marker for patients with neutropenic fever.","volume":"39","author":"Lin","year":"2011","journal-title":"Crit Care Med"},{"key":"R37-6-20210128","doi-asserted-by":"crossref","first-page":"48487","DOI":"10.1074\/jbc.R400025200","article-title":"C-reactive protein.","volume":"279","author":"Black","year":"2004","journal-title":"J Biol Chem"},{"key":"R38-6-20210128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00441-010-1018-0","article-title":"Pentraxins in innate immunity: lessons from PTX3.","volume":"343","author":"Deban","year":"2011","journal-title":"Cell Tissue Res"},{"key":"R39-6-20210128","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3324\/haematol.2011.044925","article-title":"High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients.","volume":"96","author":"Vanska","year":"2011","journal-title":"Haematologica"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e328352ead2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:36:13Z","timestamp":1786048573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-201207000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e328352ead2","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}